Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHM-029 in acute myeloid leukemia
NL-OMON61669Phase 2Not yet recruiting
- Sponsor
- CHARM Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CHM-029 in acute myeloid leukemia (AML) (4 cohorts), sponsored by CHARM Therapeutics. Primary endpoints: Incidence and severity of adverse events, Dose-limiting toxicities and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CHM-029
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON61669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61669.